$8145 | Single User
$21095 | Global License

Multiple Myeloma: KOL Insight
[2017]
[Report Updated: 01-07-2017]

Published by FirstWord Pharma: 01 Jul 2017 | 107180 | In Stock
Related Topics: Cancer , Multiple Myeloma , Myeloma , Novartis , Roche

Introduction

Will novel therapies transform the treatment of Multiple Myeloma?

In recent years, there has been significant progress in the prognosis for newly diagnosed multiple myeloma (MM) patients. While the current range of treatment options – such as Celgene’s Revlimid and Takeda’s Velcade, and combination regimens of various therapies – are well established, unmet needs persist in the market for safe and effective drugs that can deliver durable treatment responses. Sanofi’s isatuximab, AbbVie/Roche’s venetoclax and Karyopharm Therapeutics’ selinexor form part of a rich late-stage pipeline, but which candidates stand out to key opinion leaders (KOLs)? Which products and combinations are likely to succeed? Learn how KOLs see the MM market evolving in KOL Insight: Multiple Myeloma (MM). Twelve US and European KOLs provide candid insights on 5 marketed and 8 pipeline therapies targeting various aspects of the MM treatment algorithm.

Take a tour of the report now:

Methodology >

Research Objectives >

Questions Asked >

See the Multiple Myeloma therapies covered >

Find out who the 6 US and 6 European KOLs are >

Sample Pages >

Top Takeaways

Can Amgen’s Kyprolis displace Velcade (Takeda/J&J) as the protease inhibitor (PI) of choice? Kyprolis is gaining ground, but what do KOLs think about its chances as the front-line option?

Is Farydak’s (Novartis) future in the MM therapeutic strategy tenable? Farydak’s position in the treatment algorithm remains uncertain. Can it maintain its position? KOLs provide their views.

Will PharmaMar/Chugai’s Aplidin (plitidepsin) reach the market? A marketing authorisation application has been submitted for plitidepsin in Europe, but how do experts rate the potential of this VEGF-R down-regulator?

What potential do KOLs think anti-PD-1 agents have in MM? Will Keytruda (Merck & Co) and Opdivo (Bristol-Myers Squibb) find a place in the treatment algorithm?

How do KOLs rate CheckMate 602? Empliciti, Opdivo, Pomalyst (Celgene) and dexamethasone regimen is being investigated in rrMM patients. Could lack of a PI be problematic?

Will Sanofi’s isatuximab be as effective as J&J’s Darzalex? Darzalex enjoys first-to-market advantage but can isatuximab challenge its position? What role will isatuximab have in the rrMM setting?

Could Array BioPharma’s filanesib, a KIF11 protein inhibitor, provide benefit in MM? KIF11protein provides a novel target, but can it become a viable option or fall by the wayside?

Will AbbVie/Roche’s venetoclax be restricted to Bcl-2 positive patients or could it have wider application? See how experts rate venetoclax and which combinations with the drug excite them?

What do KOLs think about Karyopharm’s selinexor, the novel exportin-1 protein inhibitor? Will selinexor replicate its early promise in the larger Phase III BOSTON study?

Quotes

“When I consider the remedies available – or becoming available in the last one to three years – there are a lot of unmet needs; but I think we are on the way to convert Multiple myeloma from a malignant disease into a chronic disease.” EU Key Opinion Leader

“The high-risk patients are still having a very poor survival, so although MM in general has a significant improvement in survival with all the new agents that we have, I think we are still lagging behind significantly in the number of patients with high-risk cytogenetics that lead to progression and early death.” EU Key Opinion Leader

Sample of therapies covered

Marketed Therapies

Dazarlex (daratumumab; Genmab/Janssen Biotech)

Empliciti (elotuzumab; AbbVie/BMS)

Farydak (panobinostat; Novartis)

Kyprolis (carfilzomib; (Onyx (Amgen)

Ninlaro (ixazomib; Takeda)

Pipeline Therapies

Encorafenib (Array BioPharma)

Filanesib (Array Biopharma)

Isatuximab (Sanofi)

Nivolumab (Opdivo; Bristol-Myers Squibb)

Pembrolizumab (Keytruda; Merck & Co.)

Plitidepsin (Aplidin; PharmaMar/Chugai (Roche)

Selinexor (Karyopharm Therapeutics)

Venetoclax (AbbVie/Roche)

Sample of KOLs interviewed

KOLs from North America

Prof. Guido Tricot, MD, PhD. Director of Holden Cancer Centre’s Bone Marrow Transplant and Myeloma Program and Clinical professor, University of Iowa, IA, USA.

Prof. C. Ola Landgren, MD, PhD. Hematologic Oncologist, Chief and Professor of Medicine, Memorial Sloan Kettering Cancer Centre, New York, USA.

Prof. Irene Ghobrial, MD. Clinical Professor of Internal Medicine, Dana Farber Cancer Institute, Boston, USA.

Prof. Kenneth Anderson, MD. Kraft Family Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School and Brigham and Women's Hospital, Boston, USA.

Prof. Carol Ann Huff, MD. Associate Professor of Oncology and Medicine, Johns Hopkins University School of Medicine and Medical Director for the Johns Hopkins Kimmel Cancer Centre in Baltimore. USA.

Dr. Robert Schlossman, MD. Assistant Professor of Medicine, Dana-Farber / Harvard Cancer Institute, Harvard Medical School, Boston, USA.

KOLs from Europe

Dr Alberto Rocci, MD. Consultant haematologist, Manchester Royal Infirmary, Manchester, UK.

Dr. Charalampia Kyriakou, MD, PhD. Haematology consultant. Royal Free London NHS Foundation Trust and The North West London Hospitals NHS Trust, Northwick Park Hospital, UK.

Dr. Nicolas Blin, MD. Consultant, Department of Hematology. Nantes University Hospital, France.

Dr. Felicetto Ferrara, MD. Medical specialist in Hematology and Chief of the Hospital, Division of Hematology, Cardarelli Hospital, Napoli, Italy.

Anonymous German KOL, Dr. med., Head of Hematology, Research Group leader, Head of Quality Management. University Hospital Nurenberg-Erlangen, Germany.

Anonymous German KOL, Dr. med., Professor of medicine, Head of Oncology and Hematology department, Academic Teaching Hospital Mainz, Germany.

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with a Physician survey offering a real commercial advantage.

Your Therapy Trends Report purchase entitles you to receive a Physician survey on key developments in the CAR-T field at 6 months following publication, which is published approximately 6 months following the report's publication date.

You will receive a copy of the Physician survey once available.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Table of Contents
for Multiple Myeloma: KOL Insight [2017] [Report Updated: 01-07-2017]

  • 1. Executive Summary

    2. Research objectives

    3. Research focus

    3.1 Multiple myeloma treatment

    3.2 Darzalex and Empliciti, the first mAbs on the MM scene

    4. Marketed therapies

    4.1 Overview

    5. Proteasome inhibitors

    5.1 Overview

    5.1.1 Kyprolis (carfilzomib; Onyx (Amgen))

    5.1.2 Ninlaro (ixazomib; Takeda)

    6. HDAC inhibitors

    6.1 Overview

    6.1.1 Farydak (panobinostat; Novartis)

    7. Monoclonal antibodies

    7.1 Overview

    7.1.1 Darzalex (daratumumab; Genmab/Janssen Biotech)

    7.1.2 Empliciti (elotuzumab; AbbVie/Bristol-Myers Squibb)

    8. Pipeline therapies

    8.1 Overview

    9. Vascular endothelial growth factor-receptor antagonists

    9.1 Overview

    9.1.1 Aplidin (plitidepsin; PharmaMar/Chugai)

    10. Programmed death receptor-1 inhibitors

    10.1 Overview

    10.1.1 Keytruda (pembrolizumab; Merck & Co.)

    10.1.2 Opdivo (nivolumab; Bristol-Myers Squibb)

    11. CD38 antigen inhibitors

    11.1 Overview

    11.1.1 Isatuximab (Sanofi)

    12. Kinesin family member 11 (KIF11) protein inhibitors

    12.1 Overview

    12.1.1 Filanesib (Array BioPharma)

    13. Apoptosis stimulant/proto-oncogene protein c-bcl-2 inhibitors

    13.1 Overview

    13.1.1 Venetoclax (Venclexta/Venclyxto; AbbVie/Roche)

    14. Exportin-1 protein inhibitor/nuclear export inhibitors

    14.1 Overview

    14.1.1 Selinexor (Karyopharm Therapeutics)

    15. Conclusion

    15.1 Current and future treatment algorithm

    16. Appendix

    16.1 KOL details

    16.1.1 KOLs from North America

    16.1.2 KOLs from the EU

Additional Details

Publisher

FirstWord Pharma

Publisher Information

Reference

107180 |

Report Format

PDF

FirstWord Pharma Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?
Scope Two years after it was first submitted for approval with the FDA, Sanofi's multiple sclerosis ...
25 Nov 2014 by FirstWord Pharma USD $695 More Info
KOL Insight: Multiple Sclerosis
IntroductionRecent launches of oral therapies have brought clinical advantages and clear patient ben...
06 Oct 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: How do neurologists value multiple sclerosis medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
18 Jun 2014 by FirstWord Pharma USD $695 More Info
Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?
Scope The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in par...
05 May 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Life-cycle management strategies in multiple sclerosis – can new versions of Copaxone, Avonex drive market share retention?
Scope With Copaxone and Avonex generating global sales of .3 billion and billion for Teva and B...
26 Mar 2014 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis: KOL Insight
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
01 Dec 2013 by FirstWord Pharma USD $7,900 More Info
Consensus Outlook: Multiple Sclerosis
IntroductionOver the next five years, the global multiple sclerosis (MS) market is set to grow from ...
01 Dec 2013 by FirstWord Pharma USD $4,995 More Info
Physician Views – Which multiple sclerosis players do the best marketing job? – FirstWord polls neurologists in the US and 5EU
ScopeThe multiple sclerosis market has undergone notable change over the past 2 years, primarily due...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Sanofi secures EU approval for its multiple sclerosis treatment Lemtrada – how will neurologists use it?
ScopeWith Sanofi securing European approval for its multiple sclerosis therapy Lemtrada last week, n...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
12 Mar 2013 by FirstWord Pharma USD $7,495 More Info

This report is published by FirstWord Pharma

Download Free Report Summary PDF

Multiple Myeloma: KOL Insight [2017] [Report Updated: 01-07-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...